BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, February 16, 2025
Breaking News: BioWorld by Clarivate releases comprehensive 2024 year in review
See today's BioWorld Science
Home
» OR-641 promotes antitumoral responses through LILRB1/LILRB2 dual targeting
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
OR-641 promotes antitumoral responses through LILRB1/LILRB2 dual targeting
Nov. 17, 2023
No Comments
Oncoresponse Inc. has presented preclinical data on OR-641 as a potential immunotherapeutic for cancer.
BioWorld Science
Conferences
Society for Immunotherapy of Cancer
Cancer
Immuno-oncology